CEPHEUS Trial and MRD Outcomes in Newly Diagnosed Multiple Myeloma

Dr. Ajai Chari and NP Samantha Shenoy review the CEPHEUS trial and discuss its contribution to the evolving frontline treatment landscape in newly diagnosed multiple myeloma (NDMM). The faculty summarize the study design and examine the rationale for incorporating daratumumab into a quadruplet regimen for patients without planned upfront transplant. The discussion focuses on the achievement of deeper responses and higher rates of minimal residual disease (MRD) negativity observed with the daratumumab-containing regimen, as well as the clinical relevance of sustained MRD negativity and response depth over time. Dr. Chari and NP Shenoy explore how MRD assessment may provide additional insight into long-term disease control and discuss the potential implications of these findings for treatment duration and future management strategies. The conversation emphasizes interpretation of emerging data while considering how evolving evidence may influence clinical decision-making in patients with NDMM.